• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Nephrology

Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma

bySamuel ChanandHarsh Shah
March 10, 2021
in Nephrology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The combination of nivolumab and cabozantinib was superior to sunitinib in untreated advanced renal-cell carcinoma

2. The combination treatment caused more drug discontinuation compared to sunitinib.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In advanced renal-cell carcinoma, sunitinib is the standard of care, but the landscape of different regimens is evolving. Previous trials of single-agent cabozantinib, a tyrosine kinase inhibitor (TKI), and nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor, have been effective as the first-line treatment. This trial compared the combination of nivolumab and cabozantinib to sunitinib. The combination treatment improved overall survival, progression-free survival, and higher objective response rates. Additionally, grade 3 or above adverse events and study drug discontinuation occurred more often in the combination group. Quality of life was better maintained in the combination group compared to the sunitinib group. Study limitations included median overall survival was not reached in both groups. Overall, this trial showed the superiority of the combination treatment in advanced renal-cell carcinoma.

Click here to read the study in the NEJM

Relevant Reading: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

In-Depth [randomized controlled trial]: This phase 3, randomized, open-label clinical trial enrolled 651 patients at 125 sites in 18 countries. Patients diagnosed with untreated advanced renal cell carcinoma with a clear cell component and who received no previous systemic therapies were included in the study. Patients with active central nervous system metastases or active autoimmune disease were excluded from the study. Patients were randomized in a 1:1 ratio to either nivolumab and cabozantinib or sunitinib, respectively. The median follow-up was 18.1 months. The combination group had superior overall survival (hazard ratio [HR], 0.6; 95% confidence interval [CI], 0.40 to 0.89), progression-free survival (HR, 0.51; 95% CI, 0.41 to 0.64), and objective response (combination group, 55.7%; sunitinib group, 27.1%; P < 0.001). FKSI-19 (Functional Assessment of Cancer Therapy-Kidney Symptom Index), a measure of the quality of life, was higher in the combination group (P < 0.05). Grade 3 or above adverse events occurred in 75.3% of patients in the combination group and 70.6% of the sunitinib group. Finally, 19.7% of patients in the PD-L1/TKI group discontinued a study medication and 16.9% stopped the treatment in the sunitinib group. Overall, the combination regiment is a viable option as first-line treatment for carefully selected patients.

RELATED REPORTS

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

Lenvatinib plus pembrolizumab show similar health-related quality-of-life outcomes in patients with advanced renal cell carcinoma compared to sunitinib

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cabozantinibNivolumabrenal-cell carcinomasunitinib
Previous Post

#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes

Next Post

Different gestational diabetes screening methods cause no difference for complications

RelatedReports

Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
Increased number of daily steps linked with decreased mortality in older women

Lenvatinib plus pembrolizumab show similar health-related quality-of-life outcomes in patients with advanced renal cell carcinoma compared to sunitinib

May 2, 2022
#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
StudyGraphics

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

April 28, 2022
Oncology

Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma

April 25, 2022
Next Post
Women electing abortion more likely to be victims of domestic violence

Different gestational diabetes screening methods cause no difference for complications

Fluorophores enhance visualization for image-guided surgery [PreClinical]

Whole-genome sequencing more accurate than cytogenetic analysis in myeloid cancers

Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial

Combined division of the splenic vein a safe method for distal pancreatectomy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.